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A b s t r a c t
Introduction: DNA fragmentation factors 40 and 45 (DFF40 and DFF45) are 
final executors of apoptosis, and B-cell lymphoma 2 (Bcl-2) is a  well-rec-
ognized apoptosis inhibitor. We aimed to evaluate DFF40, DFF45 and Bcl-2 
immunoexpression in the normal human endometrium with respect to the 
glandular and stromal layer and in uterine myometrium.
Material and methods: DFF40, DFF45, and Bcl-2 expression was assessed 
via immunohistochemistry in the endometrium and myometrium collected 
postmenopausally and premenopausally during the proliferative and secre-
tory phases of the menstrual cycle.
Results: Compared to the myometrium and stroma, endometrial glands 
showed the highest DFF40 and DFF45 expression in pre- and postmeno-
pausal specimens. DFF45, but not DFF40, glandular expression dependent 
on menstrual cycle phase and DFF40 and DFF45 scoring was significantly 
lower in postmenopausal specimens. Significantly higher Bcl-2 expression 
was observed in proliferative glandular endometrium compared to secre-
tory and postmenopausal specimens. No cycle- or menopause-dependent 
changes were reported for stromal or myometrial DFF40, DFF45 or Bcl-2 ex-
pression. DFF40, DFF45 and Bcl-2 expression was independent of age, age at 
menarche and menopause, BMI, menstrual cycle and menses lengths, parity 
and gravidity.
Conclusions: The study provides important evidence regarding menstrual 
cycle-dependent changes in the expression of DFF40, DFF45 and Bcl-2 in the 
normal human endometrium, especially in the glandular layer, and shows 
that their levels are stable in the normal uterine myometrium.
Key words: endometrium, Bcl-2, menstrual cycle, DNA fragmentation 
factors 40, DFF40, DNA fragmentation factor 45, DFF45, B-cell lymphoma 2, 
uterine myometrium.
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Introduction
During the reproductive period, the human 
non-pregnant uterus undergoes hormonal-depen-
dent cyclic changes, and menstruation is the re-
sult of enhanced apoptosis [1]. Abnormal uterine 
bleeding, although non-pathognomonic, may be 
the first manifestation of endometrial pathology 
including malignancies [2]. In our previous stud-
ies we observed increased expression of apopto-
sis-related DNA fragmentation factor 45 (DFF45) 
in the endometrial glands of the secretory endo-
metrium; unfortunately, we did not investigate 
myometrial expression of DFF45 and other apop-
tosis-related factors at that time [3, 4]. 
DFF45 acts as a chaperone of DNA fragmenta-
tion factor 40 (DFF40) and serves as a  substrate 
for caspase-3 [5, 6]. The activation of the apoptotic 
cascade results in DF45 cleavage via the activated 
caspase-3, causing DFF40 release and oligonucle-
osomal DNA degradation [7]. According to Widlak 
et al., DFF45 is not a simple DFF40 inhibitor; rather, 
it acts as a DFF40 chaperone that is responsible for 
the proper folding of DFF40 to acquire its biological 
function [7]. Abundant DFF40 and DFF45 expres-
sion has been observed in ovarian endometriomas, 
endometrial cancer and other malignancies such 
as ovarian epithelial cancers, colon and esophageal 
cancers, as well as glioblastoma [8–13]. 
In contrast to the DFF40/DFF45 complex, the 
Bcl-2 protein is a core mitochondrial anti-apoptot-
ic factor that has been widely investigated with 
regard to the human reproductive tract, including 
benign endometrial and myometrial disorders, 
as well as malignancies [14–16]. Decreased Bcl-2 
was confirmed in the human secretory endome-
trium, ovarian endometriosis, human stromal cell 
lines (ThESC, ATCC, 4003) treated with raloxifene 
and also in the lamina propria lymphocytes of 
intestinal tissues from patients with Crohn’s dis-
ease [16–18]. The Bcl-2 protein, which is located 
predominantly in the mitochondrial inner mem-
brane, blocks the recruitment of proapoptotic fac-
tors such as Bax and stabilizes the mitochondrial 
membranes, thereby blunting the intrinsic death 
signaling pathway [19]. Additionally, together with 
Bcl-XL, Bcl-2 is responsible for preventing cyto-
chrome c from triggering caspase-9 activity [17]. 
The present study evaluated DFF40, DFF45, 
and Bcl-2 expression in the human physiological 
endometrium and myometrium with respect to 
menstrual cycle phases and menopausal status 
because the results may assist in the interpreta-
tion of their expression in pathological findings. 
Material and methods
Case selection
This retrospective study of paraffin-embedded 
slides was approved by the Jagiellonian Univer-
sity Review Board. The endometrial specimens 
were collected during hysteroscopic procedures in 
patients with an initial diagnosis of uterine mal-
formation (n = 21), endometrial polyps (n = 47) 
or submucosal myoma (n = 9) that finally were 
excluded based on their hysteroscopy and his-
topathological results. Myometrial samples were 
acquired from women with persistent cervical 
intraepithelial neoplasia (CIN) (19 cases of CIN2 
and 17 cases of CIN3) observed over a 12-month 
follow-up after cervical conisation) or recurrent 
(21 cases of CIN2 and 8 cases of CIN3) premalig-
nant cervical pathology, who were qualified for 
total hysterectomy as a final treatment. The pa-
thology of the uterine corpus was not observed 
in any of the cases and each patient contributed 
only one specimen. Patients who: (1) had a history 
of malignancy; (2) smoked; (3) suffered from poly-
cystic ovarian syndrome; and (4) were prescribed 
hormonal treatment within the past 5 years were 
not eligible for this study. ‘Menopause’ was de-
fined as the date of the final menstrual period, 
with no menses reported during the subsequent 
12-month period. Menstrual cycle characteristics 
were based on patient self-reports.
Immunohistochemistry and 
immunohistochemical scoring
From each case, a  representative tissue block 
was selected, deparaffinized and rehydrated as 
described previously [3, 4, 8]. A  standard immu-
nohistochemical technique was performed using 
a  rabbit polyclonal antibody to DFF45 (Abcam, 
Cambridge, UK) at a dilution of 1 : 100, a rabbit 
polyclonal antibody to DFF40 (Abcam, Cambridge, 
UK) at a  dilution of 1 : 50, and a  monoclonal 
mouse anti-human antibody to Bcl-2 (Leica Mi-
crosystems GmbH, Wetzlar, Germany) at a dilution 
of 1 : 200. Slides were incubated with 3,3’-diam-
inobenzidine for 5 min and counterstained with 
hematoxylin for 30 s; the enzymatic reactivity was 
visualized. A  colon carcinoma sample for Bcl-2, 
a human breast carcinoma tissue for DFF45, and 
human ovary tissue sections for DFF40 were used 
as positive controls. For the negative control, the 
same specimens and methods were used, but the 
primary antibodies were omitted. 
Two board-certified histopathologists blindly 
evaluated the DFF45, DFF40, and Bcl-2 staining 
for each slide using 5 high-power fields (40×) 
of maximal staining intensity. Each tissue was 
scored based on the intensity of staining (0, no 
staining; 1, weak staining; 2, moderate staining; 
and 3, strong staining) and the number of stained 
cells (0, expression in up to 10% of the cells; 1+, 
expression in 10–50% of the cells; 2+, expression 
in 51–80% of the cells; and 3+, expression in more 
than 80% of the cells). The final immunoreactivity 
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score was determined by multiplying the intensity 
scores by the extent of the positivity scores of the 
stained cells to provide a score that ranged from 
0 to 12. A discrepancy between the observations 
occurred in 18 (2.74%) cases, and the samples 
were verified again to achieve a consensus. There-
fore, K.O. and H.M-O. performed another evalua-
tion of selected slides 2 weeks after the primary 
evaluation to prevent recall bias. 
Statistical analysis
The clinical features of the study groups were 
compared using one-way analysis of variance 
(ANOVA) or the Kruskal-Wallis test, depending on 
the homogeneity of variance, while differences in 
the immunohistochemical scoring were evaluated 
using the Kruskal-Wallis test. Post hoc tests were 
used where appropriate. The non-parametric Wil-
coxon paired test was used and the Mann-Whit-
ney U  test was applied to compare scorings 
between endometrial gland stroma and myome-
trium. Clinical features were shown as the mean ± 
standard deviation (SD). Data from the immunohis-
tochemistry results were presented as the median 
and interquartile range (IQR). A multiple step-wise 
regression was used to evaluate the associations 
between DFF40, DFF45, and Bcl-2 expression and 
clinical characteristics. To evaluate the intra-rat-
er agreement of immunohistochemistry scoring, 
kappa statistics with a  p-value were applied. To 
randomize the patients who underwent evalua-
tion for the intra-rater agreement, we used the 
research randomizer (www.randomizer.org), and 
30 (20.40%) samples were randomly, separately, 
and distinctly chosen from a total of 142 samples 
regarding DFF40, DFF45, and Bcl-2 for observer 1 
and observer 2. The Guidelines for Reporting Reli-
ability and Agreement in Studies were used to verify 
these results [20]. A p-value of less than 0.05 was 
considered significant. All calculations were per-
formed using Statistica version 12.0 (StatSoft, Inc. 
2014. Statistica, version 12; www.statsoft.com).
Results
Patients and materials
The tissue samples included proliferative (n = 25), 
secretory (n = 25), and atrophic (n = 27) endome-
trium and myometrium collected during the prolif-
erative (n = 24) and secretory (n = 20) phases of 
the menstrual cycle as well as postmenopausally 
(n = 21). Table I presents clinical characteristics of 
donors.
DFF40 and DFF45 expression 
DFF40 and DFF45 nuclear expression was ob-
served in endometrium and myometrium (Figure 1). 
Median DFF40 expression in proliferatory and se-
cretory glandular endometrium was significantly 
higher compared to glandular atrophic endome-
trium, whereas no such changes were observed in 
stromal endometrium and myometrium (Figure 2, 
Table II). The significantly highest median DFF40 
scoring was observed in glandular endometrium 
compared the endometrial stroma and myometrium 
in pre- and postmenopausal specimens (Table II).
The median DFF45 expression in the endome-
trial glandular epithelium was significantly higher 
during the secretory phase of the menstrual cy-
cle than during the proliferative phase and when 
compared with postmenopausal samples (Table II, 
Figure 2). No differences in DFF45 scoring were 
observed in endometrial stroma or myometrium 
with respect to menstrual cycle phases or meno-
pausal status (Table II, Figure 2). Significantly 
higher median DFF45 expression was proved in 
endometrial glands compared to the stroma and 
myometrium with respect to phases of the men-
strual cycle and menopausal status (Table II).
Bcl-2 expression 
Bcl-2 presented cytoplasmic expression with 
the highest median scoring observed with regard 
to the glandular layer of the proliferative endome-
trium, and it differed significantly from the median 
expression observed in the endometrial stroma and 
myometrium derived during the proliferative phase 
of the menstrual cycle (Figure 1, Table II). No differ-
ences in the median Bcl-2 expression were found 
among the endometrial glandular epithelium, endo-
metrial stroma, or uterine myometrium in the post-
menopausal samples (Table II). Subsequently, only 
the expression of Bcl-2 in the endometrial glandular 
epithelium was dependent on the menstrual cycle 
phases, showing the highest median expression 
during the proliferative phase (Figure 2, Table II). 
Association of clinical features  
and DFF40, DFF45, and Bcl-2 endometrial 
and myometrial expression
The expression of DFF40, DFF45 and Bcl-2 in 
endometrial glands and stroma shows no asso-
ciation with age, age at menarche, body mass 
index (BMI), length of menstrual cycle and men-
ses, parity or gravidity, while the presence of the 
menopause was associated negatively with DFF40 
and DFF45 expression in endometrial glands 
(p = 0.006; p = 0.005, respectively), and DFF45 
glandular expression alone was dependent on the 
phase of the menstrual cycle (p = 0.002). Addition-
ally, Bcl-2 glandular expression was dependent on 
the menstrual cycle phase (p < 0.001).
Myometrial DFF40, DFF45 and Bcl-2 expression 
was independent from all the above clinical features.
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Figure 1. Expression of DFF40*, DFF45** and Bcl-2*** (200×) in normal human endometrium and myometrium
*DNA fragmentation factor 40, **DNA fragmentation factor 45, ***B-cell lymphoma 2.
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Table II. Immunoexpression of DFF40; DFF45 and Bcl-2 in normal human endometrium and normal human uterine 
myometrium in different phases of menstrual cycle and postmenopausally
Variable Menstrual cycle phase Post-menopausal
Proliferatory Secretory
Median DFF40* expression, (IQR) and min.–max.:
Endometrial glands 6.00 (2.00)
2.00–9.00
6.00 (3.00)
1.00–9.00
4.00 (2.00)
1.00–6.00
Endometrial stroma 3.00 (2.00)
0.00–9.00
3.00 (2.00)
0.00–9.00
3.00 (2.00)
1.00–9.00
Uterine myometrium 1.00 (1.00)
0.00–4.00
1.00 (0.50)
0.00–3.00
2.00 (1.00)
0.00–3.00
Median DFF45** expression (IQR) and min.–max.:
Endometrial glands 3.00 (2.00)
0.00–6.00
4.00 (2.00)
2.00–9.00
2.00 (2.00)
0.00–6.00
Endometrial stroma 2.00 (2.00)
0.00–4.00
2.00 (2.00)
0.00–6.00
1.00 (1.00)
0.00–2.00
Uterine myometrium 1.00 (1.00)
0.00–3.00
1.00 (0.00)
0.00–2.00
1.00 (0.00)
0.00–2.00
Median Bcl-2*** expression, (IQR) and min.–max.:
Endometrial glands 4.00 (0.00)
2.00–9.00
1.00 (2.00)
0.00–6.00
2.00 (3.00)
0.00–6.00
Endometrial stroma 2.00 (1.00)
0.00–4.00
1.00 (1.00)
0.00–2.00
2.00 (1.00)
0.00–6.00
Uterine myometrium 1.00 (1.50)
0.00–4.00
0.50 (1.50)
0.00–6.00
1.00 (1.00)
1.00–4.00
*DNA fragmentation factor 40, **DNA fragmentation factor 45, ***B-cell lymphoma 2, #Mann-Whitney U-test, $paired Wilcoxon test.
p 
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Validation of the intra-rater reliability for 
immunohistochemistry scoring
An almost perfect intra-rater agreement was 
confirmed with regard to the immunoscoring of 
DFF40, DFF45, and Bcl-2 expression. The following 
values were noted:
A)  The intra-rater agreement of the first investiga-
tor (i.e., investigator 1 vs. 1) for the assessment 
of DFF40 is as follows: k = 1.0 (p < 0.001); DFF45: 
k = 0.95 (p < 0.001); and Bcl-2: k = 0.96 (p < 
0.001).
B)  The intra-rater agreement of the second inves-
tigator (i.e., investigator 2 vs. 2) for the assess-
ment of DFF40 is as follows: k = 1.0 (p < 0.001); 
DFF45: k = 1.0 (p < 0.001); and Bcl-2: k = 0.96 
(p < 0.001).
Discussion
To the best of our knowledge, this study is the 
first comprehensive report of the DFF40, DFF45, 
and Bcl-2 expression in the human uterus under 
physiological conditions. Our results provide evi-
dence that menstrual cycle-dependent changes 
in the expression of DFF40, DFF45, and Bcl-2 are 
present predominantly in the endometrial glandu-
lar epithelium. These results are consistent with 
our previous findings that show changes in DFF45 
expression in the human endometrium with re-
spect to the phases of the menstrual cycle [3, 4, 8]. 
DFF40 is a major apoptotic nuclease responsi-
ble for the final DNA fragmentation in apoptosis, 
and its high and comparable expression was ob-
served in the endometrial glandular epithelium 
during both the proliferative and secretory phases 
of the menstrual cycle. Therefore, we assume that 
the tissues that show high DFF40 expression are 
potentially susceptible to apoptosis. According to 
our results, the endometrial glandular epitheli-
um showed higher potential receptivity to apop-
tosis than the endometrial stroma and uterine 
myometrium. These findings are consistent with 
those of Matsumoto et al., who observed that 
apoptosis most frequently appeared in the ep-
ithelial endometrium [21]. However, it must be 
noted that DFF40 alone is not sufficient to exe-
cute DNA fragmentation, because when DFF40 is 
in the nucleus, it remains bound to DFF45, which 
inhibits the activity of DFF40. Conversely, DFF45 
plays the dual role of DFF40 inhibitor and chap-
erone. The expression of DFF40 in the absence of 
co-expressed DFF45 results in the generation of 
inactive DFF40 aggregates [22, 23]. In our study, 
the endometrial glandular epithelium showed the 
highest DFF45 expression during the secretory 
phase of the menstrual cycle compared with that 
Immunoexpression of DNA fragmentation factor 40, DNA fragmentation factor 45, and B-cell lymphoma 2 protein in normal human 
endometrium and uterine myometrium depends on menstrual cycle phase and menopausal status
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during the proliferative phase and postmenopaus-
ally. Therefore, we assume that increased DFF45 
expression in the endometrial glandular epitheli-
um during the secretory phase of the menstrual 
cycle makes it potentially susceptible to apoptosis. 
Regression analysis proved that DFF40 and DFF45 
expression was independent from most of the 
clinical features in both the glandular and stromal 
layer of the endometrium and confirmed that the 
menopausal status was the only characteristic 
significantly influencing DFF40 expression in the 
endometrial glands. Similarly, DFF45 endometrial 
glandular expression was dependent only on the 
menstrual cycle phase and menopausal status. In 
contrast, the endometrium uterine myometrium 
showed independent DFF40 and DFF45 expres-
sion from all the analyzed clinical features.
The current study also confirmed the significant 
decrease in Bcl-2 expression that occurs predomi-
nantly during the secretory phase of the menstrual 
cycle compared with that during the proliferative 
phase in the endometrial glandular epithelium. 
Bcl-2 glandular endometrial expression was de-
pendent on the menstrual cycle phase but no other 
clinical characteristics. These results are consistent 
with those of Otsuki et al., who reported that glan-
dular endometrial cells express Bcl-2 during the 
proliferative phase of the menstrual cycle through 
the early secretory phases (but not during the late 
secretory phase) [24]. Furthermore, these authors 
found that the disappearance of Bcl-2 expression 
was correlated with the appearance of apoptosis. 
In addition, Li et al. [25] postulated that the bind-
ing of c-Jun to estrogen receptor α regulates the 
proliferative phase-specific expression of the Bcl-2 
gene in glandular endometrial cells. The high Bcl-2 
expression and low DFF45 expression that occurs 
during the proliferative phase of the menstrual 
cycle may prevent apoptosis, even when the level 
of DFF40 remains consistently high, while the de-
creased Bcl-2 and increased DFF45 expression that 
occurs during the secretory phase of the menstrual 
cycle may enhance apoptosis. 
Although our outcomes are consistent with the 
data obtained by other researchers, the present 
study has limitations. First, immunostaining was 
employed as the only study technique, and this 
semi-quantitative method does not allow us to 
directly compare the DFF40 and DFF45 levels with 
each other. However, the roles that the DFF40/
DFF45 complex and Bcl-2 play in apoptosis have 
already been explained, and this goal was not 
the aim of our study. In addition, we realize that 
an immunostaining analysis is subjective. There-
fore, two experienced pathologists evaluated 
each sample, and a discrepancy occurred only in 
2.74% of cases. These differences were reevalu-
ated thereafter to achieve a final consensus. This 
methodology is widely accepted and employed 
by many other studies regarding the expression 
of DFF45 and Bcl-2 [3, 4, 8–12, 16]. As complete 
inter-rater agreement was achieved by creating 
a  consensus in ambiguous cases, the intra-rater 
disparity was the only potential bias in our sample 
assessment. This disparity showed an almost per-
fect correlation; therefore, intra-rater bias can be 
safely excluded. Immunostaining was selected as 
an investigation method for the following reasons: 
first, this approach allows our findings to be com-
pared with previously published results; second, 
because immunochemistry is a widely used meth-
od in pathomorphological laboratories, this tech-
nique can be easily implemented and performed 
if our assessments of DFF40, DFF45, or Bcl-2 reach 
clinical applications. We also considered using an 
automatic assessment of digitalized whole slide 
images instead of pathologist-performed immu-
noscoring. An exact discernment between the 
endometrial glandular epithelium and stroma was 
required, which could be best provided by patholo-
gists. Moreover, we did not find any description of 
this method regarding the immunoscoring of the 
DFF40/DFF45 complex. Thus, to avoid the potential 
bias caused by implementation of a new method-
ology, we decided to abandon this method.
The reliable histopathological classification of 
the specimens remains the core strength of our 
study. The paraffin-embedded slides were prop-
erly stored and well prepared, which allowed for 
repeated immunostaining to be achieved for each 
sample, providing a brief period of retrospective 
analysis. Suitable selection of cases, based on 
their medical history, hysteroscopic and histopa-
thology results, allowed us to avoid bias related 
to underlying and unidentified endometrial and 
myometrial pathology.
In conclusion, the current study provides im-
portant evidence regarding menstrual cycle-de-
pendent changes in the expression of DFF40/
DFF45 and Bcl-2 in the normal human endo-
metrium, especially in the glandular layer, and 
shows that their levels are stable in the normal 
uterine myometrium. This comprehensive evalu-
ation provides a  better understanding of other 
findings concerning DFF45 and Bcl-2 expression 
in female genital tract pathologies, including ma-
lignancies. 
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